Overview

Study to Evaluate the Pharmacokinetics of SP-104

Status:
Not yet recruiting

Trial end date:
2022-02-20

Target enrollment:

Participant gender:

Summary

This open-label, 3-period, 3-treatment, randomized study will characterize the pharmacokinetics and safety and tolerability of SP-104 under fasting and fed conditions as compared to the pharmacokinetics of Naltrexone Hydrochloride Tablets, USP, 50 mg in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Scilex Pharmaceuticals, Inc.

Treatments:

Naltrexone